Protein kinase C-alpha in prostate cancer.
Lahn
M
M
Divison of Oncology Product Development, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA. mlahn@lilly.com
Sundell
K
K
Gleave
M
M
Ladan
F
F
Su
C
C
Li
S
S
Ma
D
D
Paterson
B M
BM
Bumol
T F
TF
D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis; D015153:Blotting, Western; D054713:Bryostatins; D002455:Cell Division; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D018942:Macrolides; D008297:Male; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051571:Protein Kinase C-alpha; D012333:RNA, Messenger / Q000378:metabolism
D000970:Antineoplastic Agents; D054713:Bryostatins; D007783:Lactones; D018942:Macrolides; D009363:Neoplasm Proteins; D012333:RNA, Messenger; C046785:bryostatin 1; C496628:PRKCA protein, human; D011493:Protein Kinase C; D051571:Protein Kinase C-alpha